MEdical progress: IgA nephropathy

New England Journal of Medicine

Volumn 368, Issue 25, 2013, Pages 2402-2414

  Wyatt, Robert J ^a,b   Julian, Bruce A ^c  

^a LE BONHEUR CHILDREN S HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; AZATHIOPRINE; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; COMPLEMENT COMPONENT C4D; COMPLEMENT COMPONENT C5B; COMPLEMENT COMPONENT C9; COMPLEMENT FACTOR H; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FISH OIL; GLUCOCORTICOID; IMMUNOGLOBULIN A; IMMUNOGLOBULIN A1; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MANNOSE BINDING LECTIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PROPERDIN; THYMOCYTE ANTIBODY; BIOLOGICAL MARKER;

CHROMOSOME 1Q; CHROMOSOME 22Q; CHROMOSOME 6P; CLINICAL FEATURE; COMPLEX FORMATION; DISEASE CLASSIFICATION; ELECTRON MICROSCOPY; GENE DELETION; GENETIC SUSCEPTIBILITY; GLOMERULUS FILTRATION RATE; HEMATURIA; HEREDITY; HUMAN; HYPERTENSION; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY BIOPSY; KIDNEY TRANSPLANTATION; MICROSCOPY; NEPHRECTOMY; PATHOGENESIS; PATIENT MONITORING; PRIORITY JOURNAL; PROGNOSIS; PROTEIN GLYCOSYLATION; PROTEINURIA; RENAL REPLACEMENT THERAPY; REVIEW; SURVIVAL RATE; BLOOD; CHEMICAL STRUCTURE; CHEMISTRY; PATHOLOGY; URINE;

ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BIOLOGICAL MARKERS; GLOMERULONEPHRITIS, IGA; HUMANS; IMMUNOGLOBULIN A; MOLECULAR STRUCTURE;

MLCS; MLOWN;

EID: 84879119820     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMra1206793     Document Type: Review

References (84)

1. D'Amico G. The commonest glomerulonephritis in the world: IgA nephropathy. Q J Med 1987;64:709-27. (Pubitemid 18047151)
2. Donadio JV, Grande JP. IgA nephropathy. N Engl J Med 2002;347:738-48. (Pubitemid 35203906)
3. Haas M. IgA nephropathy and Henoch-Schoenlein purpura nephritis. In: Jennette JC, Olsen JL, Schwartz MM, Silva FG, eds. Heptinstall's pathology of the kidney. 6th ed. Philadelphia: Lippincott Williams & Wilkins, 2007:423-86.
4. Berthoux F, Suzuki H, Thibaudin L, et al. Autoantibodies targeting galactose-deficient IgA1 associate with progression of IgA nephropathy. J Am Soc Nephrol 2012;23:1579-87.
5. Espinosa M, Ortega R, Gómez-Carrasco JM, et al. Mesangial C4d deposition: a new prognostic factor in IgA nephropathy. Nephrol Dial Transplant 2009;24:886-91.
6. Roos A, Rastaldi MP, Calvaresi N, et al. Glomerular activation of the lectin pathway of complement in IgA nephropathy is associated with more severe renal disease. J Am Soc Nephrol 2006;17:1724-34. (Pubitemid 43794676)
7. Miyamoto H, Yoshioka K, Takemura T, Akano N, Maki S. Immunohistochemical study of the membrane attack complex of complement in IgA nephropathy. Virchows Arch A Pathol Anat Histopathol 1988;413:77-86.
8. Conley ME, Cooper MD, Michael AF. Selective deposition of immunoglobulin A1 in immunoglobulin A nephropathy, anaphylactoid purpura nephritis, and systemic lupus erythematosus. J Clin Invest 1980;66:1432-6. (Pubitemid 11205607)
9. Allen AC, Harper SJ, Feehally J. Galactosylation of N- and O-linked carbohydrate moieties of IgA1 and IgG in IgA nephropathy. Clin Exp Immunol 1995;100:470-4.
10. Hiki Y, Odani H, Takahashi M, et al. Mass spectrometry proves under-O-glycosylation of glomerular IgA1 in IgA nephropathy. Kidney Int 2001;59:1077-85. (Pubitemid 32206870)
11. Cattran DC, Coppo R, Cook HT, et al. The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int 2009;76:534-45.
12. Davin JC. Henoch-Schönlein purpura nephritis: pathophysiology, treatment, and future strategy. Clin J Am Soc Nephrol 2011;6:679-89.
13. Wyatt RJ, Kritchevsky SB, Woodford SY, et al. IgA nephropathy: long-term prognosis for pediatric patients. J Pediatr 1995;127:913-9. (Pubitemid 26003284)
14. Wyatt RJ, Julian BA, Baehler RW, et al. Epidemiology of IgA nephropathy in central and eastern Kentucky for the period 1975 through 1994. J Am Soc Nephrol 1998;9:853-8. (Pubitemid 28209095)
15. Radford MG Jr, Donadio JV Jr, Bergstralh EJ, Grande JP. Predicting renal outcome in IgA nephropathy. J Am Soc Nephrol 1997;8:199-207. (Pubitemid 127455874)
16. Feehally J, Cameron JS. IgA nephropathy: progress before and since Berger. Am J Kidney Dis 2011;58:310-9.
17. Silva FG, Chander P, Pirani CL, Hardy MA. Disappearance of glomerular mesangial IgA deposits after renal allograft transplantation. Transplantation 1982;33:241-6.
18. Suzuki H, Kiryluk K, Novak J, et al. The pathophysiology of IgA nephropathy. J Am Soc Nephrol 2011;22:1795-803.
19. Odani H, Yamamoto K, Iwayama S, et al. Evaluation of the specific structures of IgA1 hinge glycopeptide in 30 IgA nephropathy patients by mass spectrometry. J Nephrol 2010;23:70-6.
20. Novak J, Julian BA, Mestecky J, Renfrow MB. Glycosylation of IgA1 and pathogenesis of IgA nephropathy. Semin Immunopathol 2012;34:365-82.
21. Boyd JK, Cheung CK, Molyneux K, Feehally J, Barratt J. An update on the pathogenesis and treatment of IgA nephropathy. Kidney Int 2012;81:833-43.
22. Barratt J, Eitner F, Feehally J, Floege J. Immune complex formation in IgA nephropathy: a case of the 'right' antibodies in the 'wrong' place at the 'wrong' time? Nephrol Dial Transplant 2009;24:3620-3.
23. Smith AC, Molyneux K, Feehally J, Barratt J. O-glycosylation of serum IgA1 antibodies against mucosal and systemic antigens in IgA nephropathy. J Am Soc Nephrol 2006;17:3520-8. (Pubitemid 44865295)
24. Suzuki H, Suzuki Y, Narita I, et al. Toll-like receptor 9 affects severity of IgA nephropathy. J Am Soc Nephrol 2008;19:2384-95.
25. Suzuki H, Fan R, Zhang Z, et al. Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity. J Clin Invest 2009;119:1668-77.
26. Vuong MT, Hahn-Zoric M, Lundberg S, et al. Association of soluble CD89 levels with disease progression but not susceptibility in IgA nephropathy. Kidney Int 2010;78:1281-7.
27. Kokubo T, Hiki Y, Iwase H, et al. Protective role of IgA1 glycans against IgA1 self-aggregation and adhesion to extracellular matrix proteins. J Am Soc Nephrol 1998;9:2048-54. (Pubitemid 28482152)
28. Moura IC, Centelles MN, Arcos-Fajardo M, et al. Identification of the transferrin receptor as a novel immunoglobulin (Ig)A1 receptor and its enhanced expression on mesangial cells in IgA nephropathy. J Exp Med 2001;194:417-25. (Pubitemid 32835038)
29. Kaneko Y, Otsuka T, Tsuchida Y, Gejyo F, Narita I. Integrin α1/β1 and α2/β1 as a receptor for IgA1 in human glomerular mesangial cells in IgA nephropathy. Int Immunol 2012;24:219-32.
30. Amore A, Conti G, Cirina P, et al. Aberrantly glycosylated IgA molecules down-regulate the synthesis and secretion of vascular endothelial growth factor in human mesangial cells. Am J Kidney Dis 2000;36:1242-52.
31. Lai KN. Pathogenesis of IgA nephropathy. Nat Rev Nephrol 2012;8:275-83.
32. Lai KN, Leung JC, Chan LY, et al. Activation of podocytes by mesangial-derived TNF-alpha: glomerulo-podocytic communication in IgA nephropathy. Am J Physiol Renal Physiol 2008;294:F945-F955.
33. KDIGO clinical practice guidelines for glomerulonephritis - chapter 10: immunoglobulin A nephropathy. Kidney Int Suppl 2012;2:S209-S217.
34. Kiryluk K, Julian BA, Wyatt RJ, et al. Genetic studies of IgA nephropathy: past, present, and future. Pediatr Nephrol 2010;25:2257-68.
35. Moldoveanu Z, Wyatt RJ, Lee JY, et al. Patients with IgA nephropathy have increased serum galactose-deficient IgA1 levels. Kidney Int 2007;71:1148-54. (Pubitemid 46809135)
36. Gharavi AG, Moldoveanu Z, Wyatt RJ, et al. Aberrant IgA1 glycosylation is inherited in familial and sporadic IgA nephropathy. J Am Soc Nephrol 2008;19:1008-14.
37. Hastings MC, Moldoveanu Z, Julian BA, et al. Galactose-deficient IgA1 in African Americans with IgA nephropathy: serum levels and heritability. Clin J Am Soc Nephrol 2010;5:2069-74.
38. Lin X, Ding J, Zhu L, et al. Aberrant galactosylation of IgA1 is involved in the genetic susceptibility of Chinese patients with IgA nephropathy. Nephrol Dial Transplant 2009;24:3372-5.
39. Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007;447:661-78.
40. Feehally J, Farrall M, Boland A, et al. HLA has strongest association with IgA nephropathy in genome-wide analysis. J Am Soc Nephrol 2010;21:1791-7.
41. Gharavi AG, Kiryluk K, Choi M, et al. Genome-wide association study identifies susceptibility loci for IgA nephropathy. Nat Genet 2011;43:321-7.
42. Kiryluk K, Li Y, Sanna-Cherchi S, et al. Geographic differences in genetic susceptibility to IgA nephropathy: GWAS replication study and geospatial risk analysis. PLoS Genet 2012;8(6):e1002765.
43. Yu XQ, Li M, Zhang H, et al. A genome-wide association study in Han Chinese identifies multiple susceptibility loci for IgA nephropathy. Nat Genet 2012;44:178-82.
44. Boyd JK, Barratt J. Inherited IgA glycosylation pattern in IgA nephropathy and HSP nephritis: where do we go next? Kidney Int 2011;80:8-10.
45. Torres DD, Rossini M, Manno C, et al. The ratio of epidermal growth factor to monocyte chemotactic peptide-1 in the urine predicts renal prognosis in IgA nephropathy. Kidney Int 2008;73:327-33.
46. Asao R, Asanuma K, Kodama F, et al. Relationships between levels of urinary podocalyxin, number of urinary podocytes, and histologic injury in adult patients with IgA nephropathy. Clin J Am Soc Nephrol 2012;7:1385-93.
47. Peters HP, van den Brand JA, Wetzels JF. Urinary excretion of low-molecularweight proteins as prognostic markers in IgA nephropathy. Neth J Med 2009;67:54-61.
48. Liu LL, Jiang Y, Wang LN, Liu N. Urinary mannose-binding lectin is a biomarker for predicting the progression of immunoglobulin (Ig)A nephropathy. Clin Exp Immunol 2012;169:148-55.
49. Zwirner J, Burg M, Schulze M, et al. Activated complement C3: a potentially novel predictor of progressive IgA nephropathy. Kidney Int 1997;51:1257-64. (Pubitemid 27186554)
50. Camilla R, Suzuki H, Daprà V, et al. Oxidative stress and galactose-deficient IgA1 as markers of progression in IgA nephropathy. Clin J Am Soc Nephrol 2011;6:1903-11.
51. Lundberg S, Qureshi AR, Olivecrona S, Gunnarsson I, Jacobson SH, Larsson TE. FGF23, albuminuria, and disease progression in patients with chronic IgA nephropathy. Clin J Am Soc Nephrol 2012;7:727-34.
52. Shi Y, Chen W, Jalal D, et al. Clinical outcome of hyperuricemia in IgA nephropathy: a retrospective cohort study and randomized controlled trial. Kidney Blood Press Res 2012;35:153-60.
53. Cheng GY, Liu DW, Zhang N, Tang L, Zhao ZZ, Liu ZS. Clinical and prognostic implications of serum uric acid levels on IgA nephropathy: a cohort study of 348 cases with a mean 5-year follow-up. Clin Nephrol 2013 February 8 (Epub ahead of print).
54. Haubitz M, Wittke S, Weissinger EM, et al. Urine protein patterns can serve as diagnostic tools in patients with IgA nephropathy. Kidney Int 2005;67:2313-20. (Pubitemid 41623391)
55. Julian BA, Wittke S, Novak J, et al. Electrophoretic methods for analysis of urinary polypeptides in IgA-associated renal diseases. Electrophoresis 2007;28:4469-83. (Pubitemid 350259049)
56. Rocchetti MT, Centra M, Papale M, et al. Urine protein profile of IgA nephropathy patients may predict the response to ACE-inhibitor therapy. Proteomics 2008;8:206-16.
57. Suzuki K, Honda K, Tanabe K, Toma H, Nihei H, Yamaguchi Y. Incidence of latent mesangial IgA deposition in renal allograft donors in Japan. Kidney Int 2003;63:2286-94. (Pubitemid 36605844)
58. Nair R, Walker PD. Is IgA nephropathy the commonest primary glomerulopathy among young adults in the USA? Kidney Int 2006;69:1455-8.
59. Fischer EG, Harris AA, Carmichael B, Lathrop SL, Cerilli LA. IgA nephropathy in the triethnic population of New Mexico. Clin Nephrol 2009;72:163-9.
60. Utsunomiya Y, Koda T, Kado T, et al. Incidence of pediatric IgA nephropathy. Pediatr Nephrol 2003;18:511-5. (Pubitemid 36790089)
61. Lv J, Zhang H, Zhou Y, Li G, Zou W, Wang H. Natural history of immunoglobulin A nephropathy and predictive factors of prognosis: a long-term follow up of 204 cases in China. Nephrology (Carlton) 2008;13:242-6. (Pubitemid 351341460)
62. Geddes CC, Rauta V, Gronhagen-Riska C, et al. A tricontinental view of IgA nephropathy. Nephrol Dial Transplant 2003;18:1541-8. (Pubitemid 36939626)
63. Alamartine E, Sauron C, Laurent B, Sury A, Seffert A, Mariat C. The use of the Oxford classification of IgA nephropathy to predict renal survival. Clin J Am Soc Nephrol 2011;6:2384-8.
64. Berthoux F, Mohey H, Laurent B, Mariat C, Afiani A, Thibaudin L. Predicting the risk for dialysis or death in IgA nephropathy. J Am Soc Nephrol 2011;22:752-61.
65. Li PK, Ho KK, Szeto CC, Yu L, Lai FM. Prognostic indicators of IgA nephropathy in the Chinese - clinical and pathological perspectives. Nephrol Dial Transplant 2002;17:64-9. (Pubitemid 34093011)
66. Ronkainen J, Ala-Houhala M, Autio-Harmainen H, et al. Long-term outcome 19 years after childhood IgA nephritis: a retrospective cohort study. Pediatr Nephrol 2006;21:1266-73. (Pubitemid 44203452)
67. Hotta O, Furuta T, Chiba S, Tomioka S, Taguma Y. Regression of IgA nephropathy: a repeat biopsy study. Am J Kidney Dis 2002;39:493-502. (Pubitemid 34194625)
68. D'Amico G, Minetti L, Ponticelli C, et al. Prognostic indicators in idiopathic IgA mesangial nephropathy. Q J Med 1986;59:363-78. (Pubitemid 16099605)
69. Reich HN, Troyanov S, Scholey JW, Cattran DC. Remission of proteinuria improves prognosis in IgA nephropathy. J Am Soc Nephrol 2007;18:3177-83. (Pubitemid 350223978)
70. Mackinnon B, Fraser EP, Cattran DC, Fox JG, Geddes CC. Validation of the Toronto formula to predict progression in IgA nephropathy. Nephron Clin Pract 2008;109(3):c148-c153.
71. Le W, Liang S, Hu Y, et al. Long-term renal survival and related risk factors in patients with IgA nephropathy: results from a cohort of 1155 cases in a Chinese adult population. Nephrol Dial Transplant 2012;27:1479-85.
72. Cattran DC, Reich HN, Beanlands HJ, et al. The impact of sex in primary glomerulonephritis. Nephrol Dial Transplant 2008;23:2247-53. (Pubitemid 351957578)
73. Coppo R, Troyanov S, Camilla R, et al. The Oxford IgA nephropathy clinicopathological classification is valid for children as well as adults. Kidney Int 2010;77:921-7.
74. Roberts IS. Oxford classification of immunoglobulin A nephropathy: an update. Curr Opin Nephrol Hypertens 2013 March 20 (Epub ahead of print).
75. Bellur SS, Troyanov S, Cook HT, Roberts IS. Immunostaining findings in IgA nephropathy: correlation with histology and clinical outcome in the Oxford classification patient cohort. Nephrol Dial Transplant 2011;26:2533-6.
76. Wada Y, Ogata H, Takeshige Y, et al. Clinical significance of IgG deposition in the glomerular mesangial area in patients with IgA nephropathy. Clin Exp Nephrol 2013;17:73-82.
77. El Karoui K, Hill GS, Karras A, et al. A clinicopathologic study of thrombotic microangiopathy in IgA nephropathy. J Am Soc Nephrol 2012;23:137-48.
78. Kataoka H, Ohara M, Shibui K, et al. Overweight and obesity accelerate the progression of IgA nephropathy: prognostic utility of a combination of BMI and histopathological parameters. Clin Exp Nephrol 2012;16:706-12.
79. Ponticelli C, Traversi L, Feliciani A, Cesana BM, Banfi G, Tarantino A. Kidney transplantation in patients with IgA mesangial glomerulonephritis. Kidney Int 2001;60:1948-54. (Pubitemid 33000001)
80. Berger J. Recurrence of IgA nephropathy in renal allografts. Am J Kidney Dis 1988;12:371-2.
81. Bjørneklett R, Vikse BE, Smerud HK, et al. Pre-transplant course and risk of kidney transplant failure in IgA nephropathy patients. Clin Transplant 2011;25(3):E356-E365.
82. Hiremath S, Fergusson D, Doucette S, Mulay AV, Knoll GA. Renin angiotensin system blockade in kidney transplantation: a systematic review of the evidence. Am J Transplant 2007;7:2350-60. (Pubitemid 47347851)
83. Berthoux F, El Deeb S, Mariat C, Diconne E, Laurent B, Thibaudin L. Antithymocyte globulin (ATG) induction therapy and disease recurrence in renal transplant recipients with primary IgA nephropathy. Transplantation 2008;85:1505-7.
84. Clayton P, McDonald S, Chadban S. Steroids and recurrent IgA nephropathy after kidney transplantation. Am J Transplant 2011;11:1645-9.